Traders sold shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on strength during trading on Monday following insider selling activity. $28.78 million flowed into the stock on the tick-up and $59.29 million flowed out of the stock on the tick-down, for a money net flow of $30.51 million out of the stock. Of all stocks tracked, Alnylam Pharmaceuticals had the 3rd highest net out-flow for the day. Alnylam Pharmaceuticals traded up $1.50 for the day and closed at $146.56Specifically, President Barry E. Greene sold 38,460 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $143.10, for a total value of $5,503,626.00. Following the completion of the transaction, the president now directly owns 97,544 shares of the company’s stock, valued at $13,958,546.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the transaction, the senior vice president now directly owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The disclosure for this sale can be found here. Insiders sold 232,831 shares of company stock valued at $32,776,807 over the last three months. 4.30% of the stock is currently owned by corporate insiders.
ALNY has been the subject of several research analyst reports. Credit Suisse Group set a $151.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, February 9th. B. Riley reduced their target price on Alnylam Pharmaceuticals from $205.00 to $200.00 and set a “buy” rating for the company in a research note on Friday, February 16th. BMO Capital Markets reduced their target price on Alnylam Pharmaceuticals from $165.00 to $160.00 and set an “outperform” rating for the company in a research note on Friday, February 9th. Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, January 19th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $182.00 target price on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $126.89.
The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02. The stock has a market cap of $14,486.83, a PE ratio of -27.09 and a beta of 2.67.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 41.08% and a negative net margin of 545.95%. The firm had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. The firm’s revenue for the quarter was up 116.6% compared to the same quarter last year. analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.88 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of ALNY. The Manufacturers Life Insurance Company grew its holdings in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Alnylam Pharmaceuticals by 0.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 180,058 shares of the biopharmaceutical company’s stock worth $21,156,000 after acquiring an additional 629 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in Alnylam Pharmaceuticals by 8.5% during the 3rd quarter. Great West Life Assurance Co. Can now owns 8,904 shares of the biopharmaceutical company’s stock worth $1,050,000 after acquiring an additional 695 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 10.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock worth $915,000 after acquiring an additional 700 shares in the last quarter. Finally, Public Employees Retirement Association of Colorado lifted its stake in Alnylam Pharmaceuticals by 4.4% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 17,321 shares of the biopharmaceutical company’s stock worth $2,201,000 after acquiring an additional 736 shares in the last quarter. Hedge funds and other institutional investors own 92.28% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/03/19/traders-sell-shares-of-alnylam-pharmaceuticals-alny-on-strength-after-insider-selling.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.